Dynamics of neutralizing secretory influenza antibodies after nasal administration of the NIVGRIP trivalent influenza vaccine.
The trivalent inactivated NIVGRIP influenza vaccine was administered by nasal route to 26 young adults; a matched control group was represented by 19 subjects who received a placebo. Vaccination was followed by a higher proportion of rises in the level of neutralizing secretory antibodies (70-77%) than in that of serum HAI antibodies (19-42%) to the three influenza strains contained in the vaccine. Simultaneous rises in secretory antibody titers to three and two influenza antigens occurred in 50% and 23% of the vaccinees, respectively. The vaccine conferred a protection rate of 75%, as estimated by a 7-month clinical follow-up.
D000281:Administration, Intranasal; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis*; D004341:Drug Evaluation; D005500:Follow-Up Studies; D006801:Humans; D007071:Immunoglobulin A, Secretory / Q000032:analysis*; D009980:Influenza A virus / Q000276:immunology*; D009981:Influenza B virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D009500:Neutralization Tests; D013997:Time Factors; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology
D000914:Antibodies, Viral; D007071:Immunoglobulin A, Secretory; D007252:Influenza Vaccines; D014613:Vaccines, Attenuated